Wegovy VA Coverage Pathway: How Veterans Can Access Semaglutide 2.4 mg

Start With the Current VA Record

The VA Formulary Advisor record for Wegovy injection lists non-formulary status and copay tier 3. It says a non-formulary drug request and prior approval are needed before dispensing, and that clinically appropriate formulary alternatives should be considered. The displayed data refresh was September 29, 2026. [1]

Bring the record and the current Criteria for Use to your VA appointment. Ask who submits and reviews the request, what information is missing, how to check its status and when to expect an update. The reviewed record does not provide a nationwide approval deadline. A local estimate is more useful than treating a two-to-four-week range or a committee meeting schedule as a universal rule.

The request should identify the actual product and treatment purpose. A diabetes prescription for Ozempic, a Wegovy weight-management request and another semaglutide formulation are not interchangeable coverage decisions. The VA criteria direct diabetes treatment questions to the separate Ozempic criteria. [2]

What the April 2026 Criteria Say

The current weight-management criteria require documented comprehensive lifestyle intervention addressing diet, physical activity and behavior, plus BMI of at least 27 with a weight-related comorbidity. They describe at least one documented lifestyle-intervention occasion or visit within the past year for consideration. MOVE! is one example, with other qualifying methods also possible. These criteria do not establish a universal three-to-six-month MOVE! attendance rule or a mandatory failed-drug trial for every request. Individual exceptions are handled through local pharmacy and P&T procedures. [2]

Meeting a documented criterion does not by itself establish approval or availability. Local implementation can matter. For example, VA San Diego describes scarce-resource allocation affecting weight-management medication access. That is a facility example, not a nationwide eligibility rule. Ask your own facility whether a local allocation policy affects the request and how that policy is applied. [3]

Prepare Questions and Records for the Appointment

Document prior treatment accurately without assuming it is automatically a national step-therapy requirement. Keep copies of the relevant records and the date of the criteria used. If a request is incomplete, ask which item must be corrected rather than repeating an arbitrary waiting period.

VA Copays and the Cost of a Fill

For 2026, VA tier 3 medication copays are $11 for a 1-to-30-day supply, $22 for 31-to-60 days and $33 for 61-to-90 days when a copay applies. Priority group 1 pays no medication copay. Other exemptions may also apply, and the annual medication copay cap is $700. Wegovy injection's current VA record identifies tier 3; the $5 tier 1 amount is not a universal Wegovy price. [1,4]

Confirm both the approval and the pharmacy's cost for the intended supply. A low listed copay is not evidence that a pending request has been approved. Similarly, a retail quote does not establish what VA will charge.

Manufacturer Copay Assistance and Self-Pay

The current commercial Wegovy copay offer advertises as little as $25 with a maximum $100 monthly savings. Its commercial-offer terms exclude people enrolled in government prescription coverage, including VA, TRICARE and Medicare. Changing which insurer processes a fill does not automatically make that commercial offer available. [5]

A separate NovoCare Pharmacy self-pay program explicitly includes people with commercial or government insurance who choose to pay outside insurance. Its injection offer lists $199 for each of the first two qualifying 28-day starter fills at 0.25 or 0.5 mg, then a standard $349 per 28-day fill for the listed strengths through 2.4 mg. Eligibility and timing conditions apply, and purchases through that program are not submitted for insurance reimbursement. Check its current terms before relying on a price. [6]

The offers are distinct. A support program name, a commercial copay card, a self-pay pharmacy offer and a patient-assistance program for a different medicine should not be treated as the same benefit. Ask the manufacturer which specific Wegovy option applies to your circumstances.

TRICARE Is a Separate Coverage Decision

TRICARE's published coverage announcement describes weight-loss medication access for eligible Prime, Select and related plans when its prescribing and prior-authorization requirements are met. It also states that weight-loss drugs are no longer covered for TRICARE For Life, direct-care-only beneficiaries and certain other categories following the August 31, 2025 change. A general statement that every TRICARE beneficiary has Wegovy coverage is therefore inaccurate. [7]

Its June 2026 update also describes an overseas pathway with plan, provider, local prescribing and availability requirements. The authorization process depends on where the prescription is filled. [16]

Use the current formulary and authorization form for your plan and medicine. The pharmacy cost page distinguishes beneficiary groups, pharmacy types, supply periods and covered versus non-covered drugs. It does not establish one $77 Wegovy copay for all veterans. [8]

If you have both VA and TRICARE eligibility, compare the actual approval and cost under each benefit. Do not assume the faster pathway from an unsupported universal 72-hour decision estimate. Ask the relevant pharmacy benefit about your request's status and the price of the actual fill.

Medicare's Current GLP-1 Bridge

Medicare describes a temporary GLP-1 Bridge beginning July 1, 2026 for eligible adults with Part D coverage. It includes Wegovy injection or tablet and uses specific BMI and health-condition criteria. The stated copayment is $50 for a month's supply. This is separate from regular Part D coverage for another qualifying indication, and people already receiving a GLP-1 through their Part D plan are not eligible for the Bridge. Use Medicare's current eligibility page to distinguish the two routes. [9]

What the Trials Can Tell You

STEP 1 enrolled 1,961 adults without diabetes and compared weekly semaglutide 2.4 mg with placebo alongside lifestyle intervention for 68 weeks. Mean weight change was -14.9% versus -2.4%. Gastrointestinal events led to treatment discontinuation in 4.5% versus 0.8%. These group results do not guarantee an individual's response or establish a VA approval or renewal threshold. [10]

SELECT enrolled 17,604 adults aged at least 45 with established cardiovascular disease, BMI at least 27 and no diabetes. The primary cardiovascular outcome occurred in 6.5% with semaglutide and 8.0% with placebo, with hazard ratio 0.80. The result concerns that population and endpoint; it is not a comparison with statins or evidence that every veteran receives the same benefit. [11]

Keep the clinical evidence separate from benefit eligibility. A trial result can inform a treatment discussion without establishing that a particular pharmacy or plan will cover the medicine.

If a Request Is Denied

Ask your care team for the reason, the criteria used and whether missing information, a clinical alternative or reconsideration is appropriate. VA's published help pathway starts with the care team, then the provider's supervisor or chief of service, then the medical center's patient advocate if more help is needed. The patient advocate can explain the complaint process and help route concerns. This does not guarantee a prescription approval. [12]

Avoid substituting a fixed three-month resubmission rule for the actual reason given. An incomplete record and an unfavorable clinical decision may need different responses.

Compounded Semaglutide and Follow-Up

Compounded semaglutide is a separate product decision from a VA request for branded Wegovy. FDA declared the semaglutide injection shortage resolved on February 21, 2025; its April 2026 update says semaglutide is not currently on the shortage list. An old shortage-based price claim cannot establish current availability or one average price for all compounded prescriptions. [13]

The existing distinction remains: compounded products are not FDA approved. FDA also identifies semaglutide salts as different ingredients from those in approved products. Confirm the actual product and pharmacy with your care team rather than assuming a compounded prescription is identical to Wegovy or has VA coverage. [14]

After starting treatment, confirm the actual prescription, follow-up and refill plan with the prescriber and pharmacy. The current label says insulin or sulfonylurea dose reduction may be considered; it does not specify a universal 50% reduction. A prescriber should determine any change to those medicines. A standard lab panel, fixed approval duration or responder subgroup cannot be inferred from STEP 1 for every patient. [15]